Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD

J Endocrinol Invest. 2020 Jul;43(7):1019-1026. doi: 10.1007/s40618-020-01188-7. Epub 2020 Feb 1.

Abstract

Purpose: The purpose of this study was to estimate how many individuals with severe obesity and NAFLD should be referred to hepatologists according to the EASL-EASD-EASO guidelines and whether the choice of specific indicators of liver fibrosis would significantly impact the number of referrals.

Methods: This was a single-center retrospective study of 495 individuals with severe obesity screened at our institution between 2012 and 2018 for a bariatric surgery intervention. The guidelines were applied using the NAFLD Liver Fat Score (NLFS) to assess the presence of steatosis and the NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4) and Hepamet Fibrosis Score (HFS) to assess the risk of advanced fibrosis.

Results: Three hundred and seventy-nine patients (76.6%) had evidence of liver steatosis. The application of the guidelines would lead to referral of 66.3% of patients using NFS, 31.7% using FIB-4 and 34.2% using HFS. When referrals due to abnormal liver function tests were excluded, these percentages dropped to 55.8%, 7.3% and 12.1%, respectively. The strongest inter-biomarker agreement was found between FIB-4 and HFS (κ = 0.86, 95% CI 0.815-0.910).

Conclusion: Strict application of the guidelines in individuals with severe obesity would probably lead to over-referral, although a great variability exists among the different scores.

Keywords: Fibrosis-4; Guidelines; NAFLD fibrosis score; Non-alcoholic fatty liver disease; Screening.

MeSH terms

  • Adult
  • Bariatric Surgery / statistics & numerical data
  • Biomarkers / analysis
  • Biomarkers / metabolism
  • Female
  • Gastroenterology / statistics & numerical data*
  • Guideline Adherence / standards
  • Guideline Adherence / statistics & numerical data
  • Humans
  • Italy / epidemiology
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / diagnosis*
  • Liver Cirrhosis / epidemiology
  • Liver Cirrhosis / etiology
  • Liver Function Tests / methods
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / diagnosis
  • Non-alcoholic Fatty Liver Disease / epidemiology
  • Non-alcoholic Fatty Liver Disease / therapy*
  • Obesity, Morbid / complications
  • Obesity, Morbid / diagnosis
  • Obesity, Morbid / epidemiology
  • Obesity, Morbid / therapy*
  • Practice Patterns, Physicians' / standards
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Referral and Consultation / statistics & numerical data*
  • Research Design
  • Retrospective Studies
  • Risk Factors

Substances

  • Biomarkers